Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


1 AJR Am J Roentgenol
5 BJU Int
1 BMC Cancer
1 BMC Urol
1 Br J Radiol
1 Cancer
1 Cancer Res
1 Clin Cancer Res
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
2 J Clin Oncol
4 J Nucl Med
5 J Urol
1 Magn Reson Imaging
1 PLoS One
6 Prostate
3 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. DENIFFEL D, Haider MA
    Beyond the AJR: "Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study".
    AJR Am J Roentgenol. 2021 Apr 28. doi: 10.2214/AJR.21.26048.

    BJU Int

  2. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.

  3. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.

  4. World News.
    BJU Int. 2021;127:1-3.

  5. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed         Abstract available

  6. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed         Abstract available

    BMC Cancer

  7. LEE J, Yang SW, Jin L, Lee CL, et al
    Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
    BMC Cancer. 2021;21:472.
    PubMed         Abstract available

    BMC Urol

  8. CHEN Y, Zhou Z, Zhou Y, Wu X, et al
    Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy.
    BMC Urol. 2021;21:68.
    PubMed         Abstract available

    Br J Radiol

  9. HE X, Xiong H, Zhang H, Liu X, et al
    Value of MRI texture analysis for predicting new Gleason grade group.
    Br J Radiol. 2021 Mar 11:20210005. doi: 10.1259/bjr.20210005.
    PubMed         Abstract available


  10. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
    Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
    PubMed         Abstract available

    Cancer Res

  11. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed         Abstract available

    Clin Cancer Res

  12. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  13. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
    Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
    PubMed         Abstract available

    Int J Urol

  14. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed         Abstract available

  15. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed         Abstract available

    J Clin Oncol

  16. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.

  17. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed         Abstract available

    J Nucl Med

  18. RITT P, Jobic C, Beck M, Schmidkonz C, et al
    Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2021;62:379-385.
    PubMed         Abstract available

  19. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed         Abstract available

  20. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
    Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
    PubMed         Abstract available

  21. FENDLER WP, Farolfi A
    REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.

    J Urol

  22. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    PubMed         Abstract available

  23. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    PubMed         Abstract available

  24. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    PubMed         Abstract available

  25. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    PubMed         Abstract available

  26. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    PubMed         Abstract available

    Magn Reson Imaging

  27. BOSCHHEIDGEN M, Schimmoller L, Kasprowski L, Abrar D, et al
    Arterial spin labelling as a gadolinium-free alternative in the detection of prostate cancer.
    Magn Reson Imaging. 2021 Apr 24. pii: S0730-725X(21)00068.
    PubMed         Abstract available

    PLoS One

  28. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed         Abstract available


  29. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed         Abstract available

  30. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed         Abstract available

  31. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed         Abstract available

  32. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed         Abstract available

  33. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed         Abstract available

  34. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed         Abstract available


  35. LI M, Guo J, Hu P, Jiang H, et al
    Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI.
    Radiology. 2021;299:E259.

  36. GHAI S, Finelli A, Corr K, Chan R, et al
    MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
    Radiology. 2021;299:E258.

  37. BAZARGANI S, Bandyk M, Balaji KC
    Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
    Radiology. 2020 Nov 3:202870. doi: 10.1148/radiol.2020202870.

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.